A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours (Q34499662)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours |
scientific article |
Statements
1 reference
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours (English)
1 reference
I Brana
1 reference
R Berger
1 reference
T Golan
1 reference
P Haluska
1 reference
J Edenfield
1 reference
J Fiorica
1 reference
J Stephenson
1 reference
L P Martin
1 reference
S Westin
1 reference
P Hanjani
1 reference
M B Jones
1 reference
K Almhanna
1 reference
R M Wenham
1 reference
D M Sullivan
1 reference
W S Dalton
1 reference
A Gunchenko
1 reference
J D Cheng
1 reference
L L Siu
1 reference
J E Gray
1 reference
7 October 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference